Montage-Enhanced Sternal Closure

Sponsor
University of Calgary (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03365843
Collaborator
Abyrx, Inc. (Industry)
65
1
2
50
1.3

Study Details

Study Description

Brief Summary

Post-operative recovery after cardiac surgery is influenced by early sternal bone stability. Traditional sternal closure of median sternotomy usually entails the use of 6-10 stainless steel wires. Augmenting sternal closure with techniques to enhance early bone stability should accelerate functional recovery from cardiac surgery thereby reducing post-operative pain, decreasing the need for narcotics, improving breathing and chest wall mechanics, stimulating early mobility and expediting hospital discharge.

This study is a randomized, single-centre, double-blind clinical study comparing the effects of Montage bone putty plus conventional wire closure vs conventional wire closure only on the post-operative recovery of cardiac surgery patients with full medial sternotomy.

Condition or Disease Intervention/Treatment Phase
  • Device: Montage bone putty
  • Other: Conventional Sternal Closure
Phase 2

Detailed Description

Patients undergoing cardiac surgery who are participating in the study will be randomized to either conventional wire cerclage or conventional wire closure plus the use of Montage bone putty. Patients will be followed post-operatively Day 3, 5 and at discharge as well as weeks 2, 4, 6 and months 3, 6 and 12.

Each visit will include: Pain assessment, wound assessment, sternal assessment, analgesic/antibiotic use, spirometry testing, quality of life questionaries (EQ-5D/HAQ) and determination of any adverse events. Chest x-rays will done at discharge and 3, 6, and 12 months to look at sternal healing.

This pilot study will include a total of 65 patient (40 conventional + putty / 20 conventional/ 5 initial open label with putty).

Study Design

Study Type:
Interventional
Actual Enrollment :
65 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized, single centre, double-blind clinical studyRandomized, single centre, double-blind clinical study
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description:
The participants, study coordinator and care-givers are blinded to the assigned treatment arm. Participants may be able to guess which treatment group they have been assigned. This will be assessed at the end of the study by asking participants to identify the group to which they think they have been assigned.
Primary Purpose:
Treatment
Official Title:
Montage- Enhanced Sternal Closure to Accelerate Post-Operative Recovery
Actual Study Start Date :
Oct 1, 2018
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Montage bone putty

Sternal closure with conventional wire cerclage plus Montage bone putty

Device: Montage bone putty
Application of bone putty on cut sternal surfaces prior to application of conventional wires for closure of sternum during cardiac surgery.

Other: Conventional Sternal Closure
Closure of sternum with standard wire cerclage.

Active Comparator: Conventional Sternal Closure

Conventional wire cerclage sternal closure only -- standard care.

Other: Conventional Sternal Closure
Closure of sternum with standard wire cerclage.

Outcome Measures

Primary Outcome Measures

  1. Recovery of Respiratory Function [Intervention to 6 weeks post-operative]

    The recovery of pulmonary functional capacity as measured by the return of forced vital capacity (FVC) to 80% or greater of the pre-operative baseline FVC measurement.

  2. Radiographic Sternal Integrity [Intervention to 12 months post-operative]

    No radiographic evidence of bony instability as assessed through serial chest x-rays

  3. Sternal Revision [Intervention to 12 months post-operative]

    Absence of device (wire or Montage bone putty) removal, revision or reoperation occurring over first 12 months post-operative.

Secondary Outcome Measures

  1. Post-operative Pain Assessment [Baseline to 12 months post - operative.]

    Severity of post-operative pain (survey score and analgesic use) comparing treatment vs control groups

  2. Rate of post-operative recovery [Baseline to 12 months post-operative]

    Rate of post-operative recovery as measured by health related quality of life (EQ5D) standardized assessment tool

  3. Rate of post-operative recovery [Baseline to 12 months post-operative]

    Rate of post-operative recovery as measured by physical functioning (HAQ) standardized assessment tool

  4. Sternal Wound Infections [Baseline to 12 months post-operative]

    Frequency of sternal wound infections (superficial and deep) between groups

  5. Pulmonary Complications [Baseline to 6 weeks post-operative]

    Post-operative pulmonary complications between groups

  6. Health Services resource usage [Baseline to 12 months post-operative]

    To compare the burden of health services resource usage between groups (total cost estimate)

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 79 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • undergoing non-emergent cardiac surgery ( cabg only or one valve procedure)

  • full median sternotomy approach, with or without cardiopulmonary bypass

  • English speaking

  • geographically accessible

  • written consent

Exclusion Criteria:
  • Recent CPR

  • previous cardiac surgery

  • emergency surgery ( within 24 hrs of assessment)

  • chronic lung disease

  • history of bleeding disorder

  • currently taking Vitamin E supplements

  • recent antiplatelet therapy

  • excessively poor baseline health-related quality of life or physical functioning

  • previous radiotherapy to chest, or on immunosuppressive drugs or current immunosuppressive condition

  • active significant systemic infection, history of recurrent infections,

  • cognitive impairment ( confusion, dementia, Alzheimer's, current substance abuse)

  • history of malignancy within the past year

  • recent history of significant alcohol or drug abuse

  • females who are pregnant, nursing, or child bearing potential who are not practicing a highly reliable birth control method

  • postsurgical life expectancy of less than 90 days

  • moderate to severe pectus deformity

  • participation in another study

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Calgary Calgary Alberta Canada T2N 2T9

Sponsors and Collaborators

  • University of Calgary
  • Abyrx, Inc.

Investigators

  • Principal Investigator: Paul WM Fedak, MD, PhD, University of Calgary

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr. Paul Fedak, Professor and Cardiac Surgeon, University of Calgary
ClinicalTrials.gov Identifier:
NCT03365843
Other Study ID Numbers:
  • REB17-1399
First Posted:
Dec 7, 2017
Last Update Posted:
Sep 28, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr. Paul Fedak, Professor and Cardiac Surgeon, University of Calgary

Study Results

No Results Posted as of Sep 28, 2021